Pharmacokinetics, bioavailability, and metabolism of Notoginsenoside Fc in rats by liquid chromatography/electrospray ionization tandem mass spectrometry  by He, Chunyong et al.
P
N
i
C
Z
a
M
b
c
a
A
R
R
A
A
K
N
P
M
B
L
1
i
o
P
m
p
o
o
v
T
s
(
h
0Journal of Pharmaceutical and Biomedical Analysis 109 (2015) 150–157
Contents lists available at ScienceDirect
Journal  of  Pharmaceutical  and  Biomedical  Analysis
j o ur nal ho me  page: www.elsev ier .com/ lo cate / jpba
harmacokinetics,  bioavailability,  and  metabolism  of
otoginsenoside  Fc  in  rats  by  liquid  chromatography/electrospray
onization  tandem  mass  spectrometry
hunyong  Hea,b, Jia  Lia,b, Niusheng  Xuc, Rufeng  Wanga,b, Zeyun  Lia, Li  Yanga,b,∗,
hengtao  Wanga,b,∗∗
The MOE  Key Laboratory for Standardization of Chinese Medicines and The SATCM Key Laboratory for New Resources and Quality Evaluation of Chinese
edicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Shanghai R&D Centre for Standardization of Chinese Medicines, Shanghai 201203, China
Thermo Fisher Scientiﬁc, Chromatography and Mass spectrometry Division, Shanghai 201206, China
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 2 March 2014
eceived in revised form 17 February 2015
ccepted 20 February 2015
vailable online 28 February 2015
eywords:
otoginsenoside Fc
harmacokinetics
etabolism
ioavailability
a  b  s  t  r  a  c  t
Notoginsenoside  Fc (NGFc)  is a protopanaxadiol-type  (PPD-type)  saponin  from  Panax  notoginseng,  which
has perfect  anti-platelet  aggregatory  effect.  However,  its  pharmacokinetics  and  metabolism  in vivo  remain
unknown. In this  study,  a simple  and sensitive  liquid  chromatography/electrospray  ionization  tandem
mass  spectrometry  (LC–MS/MS)  method  was  ﬁrst developed  for  the  determination  of  NGFc  in rat  plasma.
After  methanol-mediated  protein  precipitation,  separation  was  achieved  on  a C18 column  with  MS detec-
tion  operated  in negative  SRM  mode  at m/z  604.56  →  m/z  783.90  and  m/z  799.93  →  m/z  637.64  for  NGFc
and  IS, respectively.  The  assay  was  linear  over  the  concentration  range  (r  > 0.995)  with  the LLOQ  of
0.002  g/ml.  The  intra-  and  inter-day  precisions  (R.S.D.)  were  2.45–12.36%  and  3.67–14.22%, respectively;
whereas  accuracy  ranged  from  (R.R.)  93.90%  to 99.41%.  The  extraction  recovery,  stability,  and  matrix
effect  were  within  the acceptable  limits.  The  validated  LC–MS/MS  method  was  successfully  applied  toC–MS/MS the  pre-clinical  pharmacokinetic  studies  of  NGFc  in rat. After  oral  and  intravenous  administration,  NGFc
showed  dose-independent  pharmacokinetic  behaviors  with  a t1/2 of >22  h  and  its  oral  bioavailability
was 0.10–0.14%.  In  addition,  a total  of  10 metabolites  were  detected  and  structurally  characterized  by
UPLC–Q/TOF-MS  technique,  which  suggested  that  deglycosylation  was the  major  metabolic  pathway  for
NGFc in  rats.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Herb medicine has been an essential part of health care system
n Asian countries and is also considered to be a complementary
r alternative medicinal system in most Western countries [1].
anax notoginseng (Burk.) F. H. Chen, one of the most popular herb
edicines in the family of Araliaceae, has long been prescribed for
revention and treatment of cardiovascular diseases and other dis-
rders in China and other Asian countries [2–5], which has been
fﬁcially listed in the 2010 edition of Chinese Pharmacopeia with
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the name of Sanqi [6]. P. notoginseng exhibited a variety of bioactivi-
ties, including promoting blood circulation [7], immunoregulation,
anti-carcinogenesis [8], arresting bleeding, and alleviating pain
[6]. Dammarane-type triterpene saponins, i.e.,  ginsenosides and
notoginsenosides, contributed to the above-mentioned pharma-
cological effects [7], and these saponins can be divided into two
categories as protopanaxadiol (PPD) and protopanaxatriol (PPT)
types based on their aglycone skeleton [8,9]. Among these saponins,
Notoginsenoside Fc (NGFc, Fig. 1), a PPD-type saponin isolated from
the leaves of P. notoginseng, has been found to have perfect anti-
platelet aggregatory effect in our previous study [10]. However,
the pharmacokinetics and metabolism of this compound remain
unknown.
Pharmacokinetic study plays an increasingly crucial role in
drug discovery and development processes not only to further
support toxicity or clinical trials but also to optimize drug candi-
dates [11]. In other words, information on the drug metabolism
and disposition in vivo may  comprehend the mechanism of action
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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nd provide appreciable clue for structure modiﬁcations to obtain
ore effective compound. Furthermore, to know the disposition,
.e., absorption, distribution, metabolism and excretion, of a new
rug candidate is beneﬁcial for selecting the route of adminis-
ration and the dose [12]. Therefore, it would be very useful and
eaningful to obtain its pharmacokinetic proﬁles for better com-
rehension on when, where and how a drug can be effective
r toxic.
Because of the lack of chromophore in chemical structures, noto-
insenosides, including NGFc, show terminal absorption in their
ltraviolet (UV) spectra [13]. Hence, UV detector is not an optimal
ool to detect notoginsenosides as well as their trace metabolites.
vaporative light scattering detector (ELSD) is used universally
o detect compounds that have no UV absorption, which may
e suitable for determining notoginsenosides; its low sensitivity,
owever, limits the application for the detection of notogin-
enosides. Comparatively speaking, mass spectrometry, especially
andem mass spectrometry, coupled with liquid chromatogra-
hy was a powerful tool for determination and characterization
f notoginsenosides due to its high sensitivity and speciﬁcity
13–18]. Quadrupole time-of-ﬂight mass spectrometry (Q/TOF-
S)  is emerging as a powerful tool for metabolites identiﬁcation
ecause this technique provides accurate masses and elemental
ompositions of ions and reveals valuable structural information,
hich facilitates the structural identiﬁcation and increase the reli-
bility of the method [19,20]. To the best of our knowledge, several
C–MS methods have been developed for determination of NGFc
nd other saponins in P. notoginseng extracts [21–23]. However, no
ully validated liquid chromatography tandem mass spectrometry
LC–MS/MS) method has been reported for determination of NGFc
s well as its metabolites in complicated biological samples until
ow.
In this study, an LC–MS/MS method with high sensitivity and
electivity was developed and validated for the determination of
GFc in rat plasma. The reliable method was subsequently applied
o investigate the pharmacokinetic behaviors of NGFc in rats after
ntravenous and oral administration. Moreover, metabolism of
GFc in vivo was investigated using a UPLC–Q/TOF-MS technique. and ginsenoside Rg1 (GRg1, internal standard, IS).
As far as we know, this is the ﬁrst report on the pharmacokinetics
and metabolism of NGFc.
2. Experimental
2.1. Chemicals and Reagents
NGFc, Gypenoside IX, and Vinaginsenoside R7, were isolated
from P. notoginseng in our laboratory according to the previous
reports [24,25], of which the chemical structures were charac-
terized by nuclear magnetic resonance (NMR) spectroscopy, and
the purity were above 98% as determined by HPLC method. Gin-
senoside Rg1 (GRg1, internal standard, IS), Rb3, Rd, Rg3, Rh2,
20(S)-protopanaxadiol were purchased from Shanghai R&D Centre
for Standardization of Chinese Medicines (Shanghai, China). Ace-
tonitrile and methanol (HPLC grade) were purchased from Fisher
Scientiﬁc Co. (Santa Clara, USA). Ultrahigh puriﬁed water used in
this study was prepared in a Milli-Q water puriﬁcation system
(Millipore, Bedford, MA,  USA).
2.2. Animals, drug administration and sampling
Male Sprague-Dawley rats (230–250 g) were provided by SLEK
Laboratory Animal Co., Ltd. (Shanghai, China). The animals were
housed in an environmentally controlled breeding room for 7
days before starting the experiments, and fed with standard lab-
oratory food and water ad libitum except for fasting 12 h prior
to experiment. All the animal experiments were approved by
the Animal Ethics Committee of Shanghai University of Tradi-
tional Chinese Medicine. For oral administration, 15 rats were
randomly assigned into three groups, and NGFc formulated in nor-
mal  saline was orally administered to rats at the doses of 10, 25,
and 50 mg/kg, respectively. For intravenous administration, six rats
were given NGFc dissolved in normal saline via tail vein at the dose
of 5 mg/kg. Approximately 200 l blood samples were collected
into heparinized microfuge tubes at predeﬁned times. Plasma was
harvested by centrifuging the blood at 6000 × g for 10 min  and
then stored at −20 ◦C until analysis. To study the metabolism, NGFc
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(Fig. 2. MS2 spectra of NGFc
issolved in normal saline was orally administered to rats at a sin-
le dose of 100 mg/kg for the treatment group (3 rats) and equal
olume of normal saline for the blank group (3 rats). Rat urine and
ecal samples were collected from 0 h to 36 h post-dose and then
tored at −20 ◦C until analysis.
.3. Sample Pretreatment
To a 50 l portion of each plasma sample, 50 l IS (0.2 g/ml)
as added followed by addition of methanol (150 l), and the mix-
ure was vortexed for 30 s and then centrifuged at 19,000 × g for
0 min  to precipitate the denatured proteins. A 150 l aliquot of
he supernatant was mixed with equal volume of double distilled
ater. After centrifugation at 19,000 × g for 10 min, 10 l of the
upernatant was analyzed by LC–MS/MS. In addition, the plasma
amples collected from intravenous administration were diluted
0-fold with blank plasma because the NGFc concentrations were
bove the stated upper limit of the linear range, and the resulting
lasma samples were then pretreated as described above.
Each urine sample (10 ml)  was concentrated in vacuo to
 volume of 1 ml  and then deposited and slowly aspirated
hrough a Waters OASIS® HLB solid-phase extraction cartridge
re-conditioned with 1 ml  methanol, followed by 1 ml  water. The
artridges were washed with 2 ml  water before the analyte was
ecovered by using methanol (2 ml)  as eluent. The extracts were
vaporated to dryness under a gentle nitrogen stream at room
emperature and then re-dissolved with 200 l of 80% methanol.
amples were then centrifuged at 19,000 × g for 10 min  at 4 ◦C, and
 10 l of the supernatant was assayed.
Each fecal sample (1.0 g) was ultrasonically extracted with
ethanol (5.0 ml)  for 60 min  and then ﬁltered. The ﬁltrate (2 ml)
as evaporated to dryness under nitrogen gas at room tempera-
ure, and the residue was reconstituted in 200 l of 80% methanol.
he sample was then centrifuged at 19,000 × g for 10 min  at 4 ◦C,
nd a 10 l of the supernatant was analyzed.
.4. LC–MS/MS conditions
The LC system consisted of a Dionex Ultimate 3000 LC system
Thermo Electron Corporation, San Jose, CA, USA), and chromato-
raphic separations were carried out on an ACQUITY UPLC BEH C18
olumn (50 × 2.1 mm,  i.d., 1.7 m)  protected by a security column
VanguardTM BEH C18, 5 × 2.1 mm,  i.d., 1.7 m)  and thermostatedd internal standard (IS, B).
at a temperature of 45 ◦C. The mobile phase consisted of water (A)
and acetonitrile (B), at a ﬂow rate of 0.4 ml/min. The gradient elu-
tion procedure was  set as follow: 0–2 min  10–50% B, 2–3 min 50% B,
3–4 min  50–90% B, and ﬁnally reconditioning the column with 10%
B for 0.5 min. Mass spectrometry was conducted on a TSQ Vantage
triple quadrupole mass spectrometer (Thermo Electron Corpora-
tion, San Jose, CA, USA) coupled with an electrospray ionization
(ESI) source operating in negative ion mode. Tune parameters
were optimized as follows: spray voltage, 2.5 kV; sheath gas, 40
arbitrary unit; auxiliary gas, 10 arbitrary unit; capillary tempera-
ture, 300 ◦C; vaporizer temperature, 200 ◦C; collision gas (argon),
1.5 mTorr (gas pressure). Nitrogen gas was used as the sheath and
auxiliary gas. The detection of the ions was  performed in the selec-
tive reaction monitoring (SRM) mode. The precursor-to-product
ion transition for NGFc was  m/z 604.56 → m/z 783.94 and transition
of m/z 799.90 → m/z 637.64 for IS. The energy for collision-induced
dissociation was 24 eV for both NGFc and Is. All operations were
controlled by Xcalibur software version 2.2.
2.5. UPLC–Q/TOF-MS conditions
Identiﬁcation of metabolites by UPLC–Q/TOF-MS was carried
out on an ACQUITY UPLCTM (Waters Corp.) system equipped with
a binary solvent delivery system and an autosampler, and the
column efﬂuent was  monitored by a Synapt G2 quadrupole time-
of-ﬂight (Q/TOF) tandem mass spectrometer (Waters, Milford, MA)
equipped with an electrospray ionization (ESI) interface operated
in negative ion mode. The optimized parameters were set as fol-
lows: capillary voltage, 2.6 kV; sampling cone voltage, 40 V; source
temperature, 120 ◦C; desolvation temperature, 400 ◦C; desolvation
gas, 850 l/h; and cone gas, 50 l/h. Data were acquired from 100 Da
to 1300 Da and corrected during acquisition using an external ref-
erence (lock spray) composed of a solution of (2 g/ml) leucine
enkephalin (m/z 554.2615), infused at a ﬂow rate of 5 l/min.
MassLynxTM software (Version 4.1, Waters Corp., Milford, MA,
USA) was  employed to control the UPLC–Q/TOF-MS system, as
well as for data acquisition and processing. Chromatographic sep-
arations were obtained on an ACQUITY UPLCTM HSS T3 column
(100 mm × 2.1 mm,  i.d., 1.8 m;  Waters Corporation, Milford, MA,
USA) maintained at 45 ◦C. The mobile phase consisted of water (A)
and acetonitrile (B) with the following gradient elution: 0–2 min
2–8% B, 2–5 min  8–18% B, 5–9 min  18–28% B, 9–14 min  28–60%
B, 14–19 min  60–90% B, and ﬁnally the column was  reconditioned
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.6. Bioanalytical method validation
The speciﬁcity of the method was assessed by analyzing chro-
atograms of blank plasma samples from six rats with those of
lank plasma spiked with standard solution and the samples col-
ected after intravenous and oral administration of NGFc. There
hould be no interference from the endogenous substances at the
etention times of both NGFc and IS using the proposed pretreat-
ent procedure and LC–MS/MS conditions.
The calibration curves were prepared by spiking blank plasma
ith appropriate amounts of the mentioned working solutions to
roduce the calibration curve points equivalent to 0.002, 0.02, 0.1,
.2, 1, 2, 10, 20 g/ml for NGFc. Calibration curves were constructed
y plotting analyte/IS peak-area ratios against concentrations of
GFc in plasma. The linearity was assessed using a weighted (1/x2)
east square regression. The lowest limit of quantiﬁcation (LLOQ)
as deﬁned as the lowest concentration of the calibration curve at
hich the signal-to-noise ratio was more than 10 (S/N > 10).
The precision and accuracy of the assay were assessed by analyz-
ng ﬁve replicates of the QC samples at three concentration levels
0.005, 0.5 and 20 g/ml) on three consecutive days. The accuracy
nd inter- and intra-day precisions are denoted as relative recov-
ry (R.R., %) and relative standard derivation (R.S.D., %), respectively.
he R.R. was between 85% and 115% with the R.S.D. of <15%, except
t the LLOQ, where R.R. ranged from 80% to 120% and R.S.D. should
e less than 20%.
The extraction recovery of NGFc was estimated by comparing
he peak area ratio of NGFc extracted from QC samples at the lev-
ls of 0.005, 0.5 and 20 g/ml with those obtained from direct sample: (A) a blank plasma, (B) a plasma sample of LLOQ containing NGFc and IS,
 of 5 mg/kg.
injection of the analyte dissolved in the supernatant of the
processed blank plasma. The matrix effect was  determined by com-
paring the response of analyte spiked after extraction with that of
an equivalent concentration of the standard solution.
Stability of NGFc was examined in plasma samples under dif-
ferent conditions: freeze–thaw stability through three freeze/thaw
cycles; post-preparative stability during storage in the autosampler
at 10 ◦C for 8 h; long-term stability in rat plasma stored at −20 ◦C for
2 weeks; short-term stability in rat plasma stored at room temper-
ature for 24 h. The analyte was  considered stable in the biological
matrix when 85–115% of the initial concentrations were found.
2.7. Data analysis
The pharmacokinetic parameters, including the area under
the blood concentration–time curve from time zero to inﬁnity
(AUC0–∞), clearance (Cl), volume of distribution (Vd), mean resi-
dence time (MRT), and elimination half-life (t1/2), were calculated
using DAS 2.0 pharmacokinetic program (Chinese Pharmacology
Society) based on non-compartmental analysis. The maximum con-
centration (Cmax) and time of reaching maximum concentration
(tmax) were obtained from a concentration–time curve. And oral
bioavailability was  evaluated according to the following equation:
BA (%) = (AUCp.o. × Dosei.v.)/(AUCi.v. × Dosep.o.) × 100%.
3. Results and discussions
3.1. Method developmentThe LC–MS/MS operation parameters were optimized for deter-
mination of NGFc and IS. Protein precipitation with methanol
for plasma samples pretreatment was  achieved, but the solvent
1 nd Biomedical Analysis 109 (2015) 150–157
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ffect that led to abnormal peak shapes was obvious when the
upernatant was directly injected for analysis. After diluting the
upernatant with equal volume of water for assay, the solvent effect
isappeared and the peak shapes returned to normal. Because of the
n-source dissociation in positive ion mode, negative ion mode was
ence selected for analysis. NGFc showed precursor ion [M−H]−
t m/z  1209.8, and [M−2H]2− at m/z  604.56; whereas, GRg1 (IS)
xhibited different ionization mode with [M−H]− at m/z  799.90 as
he precursor ion. This may  be because NGFc is more polar than
Rg1. Ions at m/z 604.56 and m/z  799.90 were subsequently used
s precursor ions for MS2 analysis for NGFc and IS, respectively. It
as been found that fragment ions at m/z  783.94 and m/z  637.64
ere the prominent product ions for NGFc and IS, respectively
Fig. 2). Therefore, the transitions of m/z 604.56 → m/z 783.94 and
/z 799.90 → m/z 637.64 were selected for quantiﬁcation of NGFc
nd IS, respectively. Different mobile phases were tested to opti-
ize analytical performance. Acetonitrile, rather than methanol,
as ﬁnally chosen as the organic modiﬁer because it led to the good
eak shapes for both NGFc and IS as well as satisfactory running
ime (4.5 min).
.2. Method validation
Blank rat plasma samples were obtained from six different
ats and assayed to assess the speciﬁcity of the method and the
etection of interferences at the retention time of NGFc and IS.
s shown in Fig. 3, no interferences from endogenous substances
ere observed in rat plasma under the described chromatographic
onditions at retention times of 2.38 and 2.83 min, respectively.
The calibration curve showed good linearity over the range
f 0.002–20 g/ml for NGFc, with a typical regression coefﬁcient
r) of 0.9983. The LLOQ for NGFc was 0.002 g/ml (S/N > 10). The
ack calculated concentration was within 80–120% of nominal con-
entration, which indicated that the proposed method is highly
ensitive and accurate.
The results of accuracy and precision measurements assessed
y analyzing QC samples at three concentrations are presented in
able 1. As shown in Table 1, the R.S.D. (%) values of intra-day pre-
ision were less than 12.36% (n = 5) and the inter-day precision did
ot exceed 14.22% (n = 5). Mean accuracy (relative recovery, R.R., %)
f the analytes ranged from 93.90% to 99.41% (n = 5). Results showed
hat the developed method was accurate and precise.
The extraction recovery of NGFc in rat plasma was assessed
t low, medium and high concentrations. As shown in Table 2,
he average percentage of extraction recovery was found to be
03.13 ± 10.40%, 104.37 ± 5.24%, 107.86 ± 4.8% for 0.005, 0.5, and
0 g/ml, respectively (n = 5). The results of matrix effect were in
he range of 90.59–107.44% (n = 5), which suggested that there was
o signiﬁcant matrix effect in this method.
Stability studies of NGFc in rat plasma under the storage condi-
ions tested were summarized in Table 2. The results indicated that
he analyte in rat plasma was stable on storage at room temperature
or 24 h, on storage for two weeks under −20 ◦C, in freeze–thraw
tability, and on storage in autosampler at 10 ◦C, respectively, with
he relative recovery (R.R., %) ranging from 87.92% to 110.02%
n = 5).
.3. Pharmacokinetic study
The validated method has been successfully applied to phar-
acokinetic study of NGFc in rats after oral and intravenous
dministration. The mean plasma concentration–time proﬁles of
GFc after intravenous administration (5 mg/kg) are shown in
ig. 4A, with pharmacokinetic parameters listed in Table 3. It can
e seen from Fig. 4A that NGFc had a slow elimination from plasma
fter intravenous administration, with a long t1/2 of 27.62 ± 3.07 h.Fig. 4. Mean plasma concentration–time curves of NGFc after intravenous adminis-
tration at the dose of 5 mg/kg (A, n = 6) and oral (B, n = 5) administration at the doses
of  10, 25, 50 mg/kg. Vertical bars represent S.D.
The apparent volume of distribution (Vd) was 0.16 ± 0.01 l/kg, sug-
gesting that NGFc was poorly distributed into organism or tissues.
The mean plasma concentration–time proﬁles of NGFc after oral
administration (10, 25, and 50 mg/kg) are presented in Fig. 4B,
with pharmacokinetic parameters summarized in Table 3. After
oral administration, NGFc was absorbed rapidly from the gastroin-
testinal tract, detected in plasma from the ﬁrst blood sampling
time (15 min). NGFc was also slowly eliminated from plasma
with a long t1/2 more than 22 h and AUC0–∞ values were pro-
portional to oral doses. For example, the AUC0–∞ values were
2.32 ± 0.58 g h/ml, 7.19 ± 1.27 g h/ml, and 17.65 ± 3.64 g h/ml,
for 10, 25, and 50 mg/kg, respectively. The oral BA values were dose-
independent, at 0.10%, 0.12% and 0.14% for doses of 10, 25, and
50 mg/kg, respectively, suggesting dose-independent pharmacoki-
netic characteristics. The low oral bioavailability may  be attributed
to its poor intestinal mucosal permeability.
3.4. Metabolites identiﬁcation
By comparison with the blank samples, precursor ions uniquely
found in NGFc-dosed samples were considered the potential
metabolites and thus used for subsequent MS2 analysis. Ten poten-
tial metabolites were observed and structurally identiﬁed based on
their MS  and MS2 spectra. Seven of the metabolites were further
conﬁrmed by matching their fragmentation patterns and retention
times with their reference standards. According to the metabolite
proﬁles, the in vivo proposed metabolic pathways of NGFc were pre-
dicted as shown in Fig. 5. The elemental compositions observed and
calculated masses, mass errors, and characteristic fragment ions of
the proposed metabolites were summarized in Table 4.Metabolites M1  and M2  were eluted at 11.97 and 12.09 min,
respectively. Both of them showed an accurate [M−H]− ion at
m/z 1077.5867 (−2 ppm, elemental composition of C53H89O22),
132 Da lower than that of NGFc, suggesting both of the metabolites
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Table  1
Intra- and inter-day precision and accuracy of the LC–MS/MS method for the determination of NGFc in rat plasma at low, medium and high concentrations (n = 5). Data were
expressed as mean ± S.D.
Nominal conc. (g/ml) Measured conc. (g/ml) Accuracy (R.R., %) Intra-day precision (R.S.D., %) Inter-day precision (R.S.D., %)
0.005 0.0048 ± 0.0002 95.86 ± 4.33 4.59 3.67
0.5  0.49 ± 0.05 99.41 ± 10.56 12.36 10.71
20  18.78 ± 1.38 93.90 ± 6.90 2.45 14.22
Table 2
The extraction recovery, matrix effect and stability of NGFc in rat plasma (n = 5).
Nominal Conc. (g/ml) Matrix effect (%) Extraction recovery (%) Stability (R.R., %)
Freeze–thaw Long-term Short-term Post-preparation
0.005 107.44 ± 14.98 103.13 ± 10.40 97.55 ± 10.89 98.64 ± 4.22 95.56 ± 10.55 95.83 ± 7.70
0.5  90.59 ± 6.41 104.37 ± 5.24 100.66 ± 5.91 100.15 ± 12.88 110.02 ± 3.81 100.79 ± 7.18
20  100.43 ± 6.54 107.86 ± 4.80 90.70 ± 3.31 95.95 ± 11.61 93.67 ± 4.29 87.92 ± 1.45
Data were expressed as mean ± S.D.
Table 3
Pharmacokinetic parameters of NGFc after intravenous administration (n = 6) at the dose of 5 mg/kg and oral administration (n = 5) at the doses of 10, 25, 50 mg/kg. Data were
expressed as mean ± S.D.
Parameters p.o. (n = 5) i.v. (n = 6)
10 (mg/kg) 25 (mg/kg) 50 (mg/kg) 5 (mg/kg)
AUC0–t (g h/ml) 2.14 ± 0.47 6.27 ± 1.01 16.67 ± 3.24 1118.11 ± 65.34
AUC0–∞ (g h/ml) 2.32 ± 0.58 7.19 ± 1.27 17.65 ± 3.64 1217.72 ± 86.24
MRT0–t (h) 27.32 ± 1.82 27.37 ± 1.86 28.69 ± 1.35 27.90 ± 0.68
MRT0–∞ (h) 35.64 ± 5.88 33.17 ± 2.5 34.30 ± 2.87 36.70 ± 2.67
t1/2 (h) 27.28 ± 7.18 22.33 ± 3.45 22.27 ± 2.12 27.62 ± 3.07
tmax (h) 3.00 ± 1.41 10.45 ± 3.58 6.67 ± 3.27
Vd (l/kg) 173.01 ± 41.16 113.21 ± 22.03 83.68 ± 22.83 0.16 ± 0.01
56 ± 0
19 ± 0
12 
w
w
w
w
c
3
(
mCl  (l/kg/h) 4.54 ± 1.18 3.
Cmax (g/ml) 0.083 ± 0.024 0.
BA  (%) 0.10 0.
ere dexylosylated metabolites. The fragment ion m/z at 945.5450
ere formed by the neutral loss of xylose from [M−H]− ion,
hile the fragment ion at m/z  783.4904, 621.4374, and 459.3833
ere formed by the neutral loss of one, two, and three glu-
oses from the m/z 945.5450. Furthermore, fragment ion at m/z
75.2903 was  observed, which resulted from the loss of side chain
CH2CH2CH C(CH3)2 at C-20 position from the m/z  459.3833
−84 Da). By comparing the chromatographic retention times and
ass spectral fragmentation patterns with reference standards, M1
Fig. 5. Proposed metabolic pathways of NGFc after oral administ.60 2.65 ± 0.80 0.0042 ± 0.0004
.03 0.46 ± 0.11 53.67 ± 11.83
0.14
and M2  were unambiguously identiﬁed as ginsenoside Rb3 and
Vinaginsenoside R7, respectively.
Metabolites M3  was  detected at 12.38 min. ESI-MS gave an accu-
rate [M−H]− ion at m/z 945.5455 (3.4 ppm, elemental composition
of C48H81O18), 264 Da lower than that of NGFc. This ﬁnding sug-
gested that M3 was  the double dexylosylated metabolite of NGFc.
MS2 fragmentation of M3  showed fragment ions at m/z  783.4903,
621.4366, and 459.3841, which resulted from the stepwise cleavage
of glucose from the [M−H]− ion. Comparing the chromatographic
ration at the dose of 100 mg/kg (Glu, glucose; Xyl, xylose).
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Table 4
The predicted elemental compositions, observed masses and calculated masses, retention times, characteristic fragment ions, and description of NGFc metabolites in rat
urine  and feces.
Metabolite Retention time
(min)
Elemental
compositions
Measured mass
[M−H]− (m/z)
Calculated
mass [M−H]−
(m/z)
Error (ppm) Fragment ions Metabolite
description
Sourcea
M1  11.97 C53H89O22 1077.5867 1077.5845 2 945.5450,
915.5297,
783.4904,
621.4372,
459.3833,
375.2903,
161.0445,
149.0447
Ginsenoside
Rb3
U, F
M2  12.09 C53H89O22 1077.5853 1077.5845 0.7 945.5438,
915.5314,
783.4902,
621.4374,
459.3845,
375.2882,
161.0447
Vinaginsenoside
R7
U, F
M3  12.38 C48H81O18 945.5455 945.5423 3.4 783.4903,
621.4366,
459.3841,
375.2880,
161.0435
Ginsenoside Rd U, F
M4  13.21 C47H79O17 915.5326 915.5317 1 783.4899,
621.4365,
459.3833,
375.2894,
161.0454
Notoginsenoside
ST4
U, F
M5  13.82 C47H79O17 915.5319 915.5317 0.2 783.4891,
621.4375,
459.3841,
375.2890,
161.0454
Gypenoside IX U, F
M6  15.08 C41H69O12 753.4791 753.4789 0.3 621.4365,
459.3836
Gypenoside
XIII
U, F
M7  14.35 C42H71O13 783.4875 783.4895 −2.6 621.4371,
459.3830
Ginsenoside
Rg3
U
M8  16.16 C30H61O8 621.4357 621.4366 −1.4 459.3843,
375.2883,
161.0468
Ginsenoside CK U, F
M9  16.4 C30H61O8 621.437 621.4366 0.6 459.3843,
375.2883
Ginsenoside
Rh2
U
M10  19.33 C30H50O3 459.3813 459.3838 −5.4 375.2903 20 (S)-
protopanaxadiol
F
r
e
R
r
9
l
i
9
r
F
r
p
w
I
a
s
t
t
r
ia U represents urine samples, and F refers to fecal samples.
etention time and mass spectral fragmentation patterns with ref-
rence standard, M3 was unambiguously identiﬁed as ginsenoside
d.
Metabolites M4  and M5  were eluted at 13.21 and 13.82 min,
espectively. Both of them had an accurate [M−H]− ion at m/z
15.5335 (−2 ppm, elemental composition of C47H79O17), 162 Da
ower than that of M1  or M2.  MS2 fragmentation showed fragment
on at m/z  783.4899, which formed by the loss of xylose from m/z
15.5335 (−132 Da). Fragment ions at m/z  621.4365 and 459.3833
esulted from the stepwise cleavage of glucose from m/z 783.4899.
urthermore, fragment ion at m/z  375.2894 was observed, which
esulted from the loss of side chain CH2CH2CH C(CH3)2 at C-20
osition from the m/z  459.3833 (−84 Da). Therefore, M4  and M5
ere tentatively identiﬁed as notoginsenoside ST4 and gypenoside
X, respectively.
Metabolites M6 was detected at 15.08 min. ESI-MS showed an
ccurate [M−H]− ion at m/z 753.4791 (0.3 ppm, elemental compo-
ition of C41H69O12), 162 Da lower than that of M5,  which suggested
hat M6  was the dexylosylated metabolite of M5.  MS2 fragmenta-
ion showed fragment ions at m/z  621.4365 and 459.3836, which
esulted from the stepwise cleavage of glucose from the [M−H]−
on. M6  was therefore tentatively identiﬁed to be gypenoside XIII.Metabolites M7  was eluted at the retention time of 14.35 min,
which had an accurate [M−H]− ion at m/z 783.4875 (−2.6 ppm,
elemental composition of C42H71O13), 132 Da lower than that of
M4.  MS2 fragmentation showed fragment ions at m/z 621.4371 and
459.3830, which resulted from the stepwise cleavage of glucose
from the [M−H]− ion. Fragment ion at m/z  375.2883 formed by
the loss of side chain CH2CH2CH C(CH3)2 at C-20 position from
the m/z 459.3830 (−84 Da). Comparing the chromatographic reten-
tion time and mass spectral fragmentation patterns with reference
standard, M7 was  unambiguously identiﬁed as ginsenoside Rg3.
Metabolites M8  and M9  were eluted at 16.16 and 16.40 min,
respectively. Both of them had an accurate [M−H]− ion at m/z
621.4384 (2.9 ppm, elemental composition of C30H61O8). MS2 frag-
mentation of M8  showed fragment ion at m/z 459.3843, which
formed by the loss of glucose from m/z 621.4384 (−162 Da). By
comparing the chromatographic retention times and mass spectral
fragmentation patterns with reference standards, M8 was  unam-
biguously identiﬁed as ginsenoside Rh2. MS2 fragmentation of M9
was identical to that of M8,  suggesting that M8  and M9  were iso-
mers. Therefore, M9  was  tentatively identiﬁed as ginsenoside CK.
Metabolites M10  was eluted at the retention time of 19.33 min,
which had an accurate [M−H]− ion at m/z 459.3813 (−5.4 ppm,
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lemental composition of C30H51O3), 162 Da lower than that of M8
nd M9.  MS2 fragmentation showed fragment ions at m/z  375.2903,
esulting from the loss of side chain CH2CH2CH C(CH3)2 at C-20
osition from m/z 459.3843 (−84 Da). Comparing the chromato-
raphic retention times and mass spectral fragmentation patterns
ith reference standard, M10  was unambiguously identiﬁed as
0(S)-protopanaxadiol (PPD).
. Conclusions
In summary, a simple and sensitive LC–MS/MS method with
LOQ of 0.002 g/ml for determination of NGFc in rat plasma was
eveloped and validated for the ﬁrst time. This novel method has
een successfully applied for the pharmacokinetic studies of NGFc
n rat. NGFc has been found to have a slow elimination from plasma
ith a long t1/2 (approximately 22–30 h). When given orally, NGFc
howed dose-independent pharmacokinetic characteristics, and its
ral BA was approximately 0.10–0.14%. Moreover, in vivo metabolic
tudy of NGFc using UPLC–Q/TOF-MS suggested that deglycosyla-
ion is the major metabolic pathway for NGFc in rats. As far as we
now, this is the ﬁrst study on the in vivo pharmacokinetics and
etabolism of NGFc.
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